BioCentury
ARTICLE | Clinical News

Dolutegravir: Interim Phase IIb data

July 25, 2011 7:00 AM UTC

Interim data from the ongoing, double-blind, dose-ranging Phase IIb SPRING-1 trial (ING112276) in 205 treatment-naïve HIV patients showed that once-daily 10, 25 and 50 mg dolutegravir reduced mean HIV-1 RNA levels from baseline to week 48 by 4.42, 4.38 and 4.58 log10 copies/mL, respectively, vs. 4.46 log10 copies/mL for once-daily 600 mg Sustiva efavirenz. Additionally, the proportion of patients with HIV-1 RNA levels <50 copies/mL at week 48 was 91%, 88% and 90% for low, mid- and high-dose dolutegravir, respectively, vs. 82% for Sustiva. Additionally, across all doses dolutegravir non-significantly increased CD4+ T cells from baseline to week 48 by 231 cell/mm 3 vs. 174 cells/mm 3 for Sustiva (p<0.076). Mean change from baseline in LDL-C for dolutegravir was 0.55 mg/dL compared to 15.88 mg/dL for Sustiva. Patients received Epzicom abacavir/lamivudine or Truvada emtricitabine/tenofovir in combination with either dolutegravir or Sustiva. Data were presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article